WallStreetZenWallStreetZen

NASDAQ: CHRS
Coherus Oncology Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Coherus Oncology earnings were -$132.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest CHRS earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$20.6M, down 46.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CHRS reported annual earnings of $168.0M, with 489.4% growth.

CHRS earnings history

Current Revenue
$50.9M
Current Earnings
-$132.1M
Current Profit Margin
-259.4%

CHRS Return on Equity

Current Company
-183.4%
Current Industry
-6.9%
Current Market
29.1%
CHRS's Return on Equity (-183.4%)... subscribe to Premium to read more.
High Return on Equity Performance

CHRS Return on Assets

Current Company
-42.9%
Current Industry
-7%
CHRS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when CHRS announces earnings.

CHRS Return on Capital Employed

Current Company
-106.38%
Current Industry
-1.4%
CHRS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CHRS vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
CHRS-$119.44M-$132.13MN/A-$1.06
ADAG-$16.85M-$17.61MN/A-$0.38
CRBP-$101.70M-$101.90MN/A-$6.11
YDES-$8.10M-$8.31MN/A-$0.12
ACOG-$24.17M-$25.14MN/A-$1.34
View Top Biotech Stocks

Coherus Oncology Earnings Reports & History FAQ

What were Coherus Oncology's earnings last quarter?

On CHRS's earnings call on Aug 5, 2026, Coherus Oncology (NASDAQ: CHRS) reported Q2 2026 earnings per share (EPS) of -$0.13, up 105.06% year over year. Total CHRS earnings for the quarter were -$20.63 million. In the same quarter last year, Coherus Oncology's earnings per share (EPS) was $2.57.

If you're new to stock investing, here's how to buy Coherus Oncology stock.

Is Coherus Oncology profitable or losing money?

As of the last Coherus Oncology earnings report, Coherus Oncology is currently losing money. Coherus Oncology's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$132.13 million, a 173.51% decrease year over year.

What was CHRS's earnings growth in the past year?

As of Coherus Oncology's earnings date in Aug 5, 2026, Coherus Oncology's earnings has grown year over year. CHRS earnings in the past year totalled -$132.13 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.